SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                              ____________________
                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     Date of Report (Date of the earliest event reported): October 25, 2004
                              ____________________

                          PRIMEDEX HEALTH SYSTEMS, INC.
             (Exact name of registrant as specified in its charter)

            New York                                      13-3326724
(State or other jurisdiction of                (IRS Employer Identification No.)
 incorporation or organization)               

                                     0-19019
                            (Commission File Number)

                               1510 Cotner Avenue
                          Los Angeles, California 90025
               (Address of principal executive offices) (Zip Code)

                                 (310) 478-7808
              (Registrant's telephone number, including area code)







ITEM 7.01.  REGULATION FD DISCLOSURE.

         On October 25, 2004, Primedex Health Systems, Inc. issued a press
release announcing its exclusive offering in the Los Angeles area of a new and
completely non-invasive procedure to treat symptomatic uterine fibroids using
the ExAblate(R) 2000 technology which received FDA approval on Friday, October
22, 2004. The press release is attached as Exhibit 99.1 to this report and is
incorporated herein by this reference.

         The information in this Current Report on Form 8-K, including the
exhibits thereto, will not be treated as filed for the purposes of Section 18 of
the Securities Exchange Act of 1934 or otherwise subject to the liabilities of
that section. This information will not be incorporated by reference into a
filing under the Securities Act of 1933, or into another filing under the
Securities Exchange Act of 1934, unless that filing expressly refers to specific
information in this report.



ITEM 9.01. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

         (c) Exhibits

         EXHIBIT NUMBER           DESCRIPTION 
         --------------           ----------- 
             99.1                 Press release dated October 25, 2004.

                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  October 25, 2004                     PRIMEDEX HEALTH SYSTEMS, INC.


                                            By: /s/ Howard G. Berger, M.D.
                                                --------------------------------
                                                Howard G. Berger, M.D.
                                                President







                                  EXHIBIT INDEX


        EXHIBIT NUMBER                DESCRIPTION    
        --------------                -----------    
              99.1            Press release dated October 25, 2004.